Pfizer/Eyetech Macugen On Fast Track To FDA Advisory Committee
Executive Summary
Pfizer/Eyetech's Macugen will be reviewed for the treatment of "wet" age-related macular degeneration by FDA's Dermatologic & Ophthalmic Drugs Advisory Committee on Aug. 27